CONNECT WITH US
Web3 & Blockchain

Web3 & Blockchain

INJ vs. INJC: Injective (INJ)compares direct token holding with ETF shares

Blockchain.News logo

Published on

Add as a preferred source on Google
INJ vs. INJC: Injective (INJ)compares direct token holding with ETF shares

Injective (INJ)outlines the differences between holding INJ directly and owning INJC ETF shares, including custody, staking, access and costs.

Injective (INJ)has published a side-by-side comparison of direct INJ ownership and shares of the Canary Staked INJ ETF, framing the choice as one between self-custodied token exposure and brokerage-account access. The guide says INJ holders keep the token in a wallet or exchange account, while INJC investors own fund shares held in a brokerage account, with staking built into the product structure.

According to the Oct. 14, 2026 guide from Injective, INJ is the network’s native asset and is used to pay fees, stake to secure the chain and vote on upgrades. The company says direct holders control their own keys, can choose a validator and can use INJ across Injective apps, while INJC holders do not vote, do not move tokens onchain and cannot redeem shares for INJ. The guide adds that the fund’s custodian is BitGo and that the fund stakes part of its INJ while keeping some unstaked to meet redemptions.

Injective’s comparison also separates the trading venues and cost structures. INJ trades 24/7 on crypto venues, while INJC trades on Nasdaq during market hours. The guide says direct INJ holders may face exchange fees, network withdrawal fees and validator commission if staking, while INJC investors face a sponsor fee charged as an annual percentage of assets, staking-related fees taken from rewards and any brokerage commission or bid-ask spread. The guide does not provide a fee rate for the ETF in the supplied material.


Source link
Related Topics:Web3 & Blockchain

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.